PHC Holdings Corporation (2GY.F)
| Previous Close | 6.65 |
| Open | 6.85 |
| Bid | 6.95 x N/A |
| Ask | 7.20 x N/A |
| Day's Range | 6.85 - 6.95 |
| 52 Week Range | 6.55 - 10.60 |
| Volume | |
| Avg. Volume | 12 |
| Market Cap | 906.537M |
| Beta (5Y Monthly) | 0.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.85 |
| Earnings Date | May 10, 2024 |
| Forward Dividend & Yield | 0.44 (6.62%) |
| Ex-Dividend Date | Mar 28, 2024 |
| 1y Target Est | N/A |
Business WireEversense® CGM System Receives iCGM Designation by the US FDA
GERMANTOWN, Md. & PARSIPPANY, N.J., April 30, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes and Ascensia Diabetes Care, a global diabetes care company, announced that Eversense® has been granted an integrated CGM (iCGM) designation by the US Food and Drug Administration (FDA).
PR NewswireSAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS
Ascensia Diabetes Care, a global diabetes care company and a subsidiary of PHC Holdings Corporation (TSE: 6523), and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, have announced a significant extension of the Eversense Payment Assistance and Simple Savings (PASS) Program. Designed to help people in the U.S. access the Eversen
- PR Newswire
MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM
Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable C
